Depomed, Inc., of Menlo Park, Calif., has received approval for 1,000-mg strength tablets of Glumetza (metformin hydrochloride extended-release tablets), which is indicated alone or in combination with a sulfonylurea or insulin as an adjunctive therapy to improve glycemic control in adult type 2 diabetes patients.